Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Chief Operating Officer | July 18, 2023 | July 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sagimet Biosciences Inc.
Report date July 18, 2023 · Filed July 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.51 · Expires 2033-04-19 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-18 · Disposition to issuer · Disposed 242,142 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.51 · Expires 2033-04-19 | Direct | 242,142 |
Reported balance
After 2023-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-18 · Grant · Acquired 242,142 · Balance 242,142 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 242,142 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082730 · tm2321276-19_4seq1.xml · derivative · entry 2 Rimac Anthony M · CIK 0001604562 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,142 Underlying: Series A Common Stock · 242,142 shares Expires 2033-04-19 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:18 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 242,142 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001104659-23-082730 · tm2321276-19_4seq1.xml · derivative · entry 1 Rimac Anthony M · CIK 0001604562 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 242,142 shares Expires 2033-04-19 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.